Abstracts

Cumulative HIV Care Measures Highly Associated With Acute Myocardial Infarction

Background: After accounting for established risk factors, people living with HIV (PLWHIV) have a 50-75% greater risk of acute myocardial infarction (AMI) than uninfected individuals. Several underlying causes for this association have been suggested including ongoing chronic inflammation, immune suppression, and a greater burden of anemia, renal disease, liver disease, and hepatitis C infection. While…

HIV-Infected Veterans and the New ACC/AHA Cholesterol Guidelines: Got Statins?

Background: Cardiovascular disease, an HIV-associated non-AIDS related (HANA) condition, is an emerging threat to people living with HIV; thus, appropriate primary and secondary prevention is critical. In November 2013 updated guidelines for cholesterol treatment from the American College of Cardiology and the American Heart Association (ACC/AHA) substantially expanded recommendations for statin use among the general…

Evaluation of the ACC/AHA CVD Risk Prediction Algorithm Among HIV-Infected Patients

Background: The 2013 American College of Cardiology (ACC)/ American Heart Association (AHA) cardiovascular disease (CVD) risk prediction algorithm (Pooled Cohorts Equations) has not previously been evaluated in HIV populations. Methods: Framingham Risk Scores (FRS) and ACC/AHA risk scores were calculated for patients in a longitudinal HIV clinical care cohort during a 3-year interval ending January…

In Silico Simulation of Interaction Between Rifampicin and Boosted Darunavir

Background: The optimization of antiretroviral regimens in HIV-infected patients co-administered with anti-TB drugs is challenging since rifampicin (RIF), a principal element of the anti-TB therapy, is a strong inducer of key metabolic enzymes. Physiologically-based pharmacokinetic (PBPK) modelling represents an innovative approach to simulate clinical scenarios in the absence of clinical data, by integrating in vitro…

Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics

Background: Physiological changes during pregnancy coupled with single nucleotide polymorphisms (SNPs) in drug disposition genes are known to alter the pharmacokinetics (PK) of many drugs. In the present study the magnitude of pregnancy-induced changes in efavirenz (EFV) PK in genetically-defined subgroups was investigated. Methods: This was an observational study with an enrichment design conducted in…